Brokerages expect Corium International Inc (NASDAQ:CORI) to post earnings per share (EPS) of ($0.39) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Corium International’s earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.33). Corium International reported earnings per share of ($0.43) during the same quarter last year, which indicates a positive year over year growth rate of 9.3%. The firm is scheduled to announce its next earnings results on Thursday, August 2nd.

On average, analysts expect that Corium International will report full-year earnings of ($1.59) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.50). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.46) per share, with EPS estimates ranging from ($1.74) to ($1.09). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Corium International.

Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.04). Corium International had a negative return on equity of 273.01% and a negative net margin of 156.05%. The business had revenue of $10.06 million for the quarter, compared to the consensus estimate of $7.07 million.

A number of brokerages recently issued reports on CORI. ValuEngine lowered Corium International from a “buy” rating to a “hold” rating in a research note on Friday, July 6th. BidaskClub downgraded Corium International from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 3rd. Zacks Investment Research downgraded Corium International from a “hold” rating to a “sell” rating in a report on Thursday, May 17th. HC Wainwright set a $14.00 price objective on Corium International and gave the stock a “buy” rating in a report on Tuesday, May 15th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $14.00 price objective on shares of Corium International in a report on Friday, May 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Corium International currently has a consensus rating of “Hold” and an average target price of $13.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. increased its holdings in shares of Corium International by 47.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after acquiring an additional 15,909 shares during the period. California Public Employees Retirement System purchased a new position in shares of Corium International in the 4th quarter valued at $310,000. Wells Fargo & Company MN increased its holdings in shares of Corium International by 280.2% in the 4th quarter. Wells Fargo & Company MN now owns 44,271 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 32,628 shares during the period. BlackRock Inc. increased its holdings in shares of Corium International by 42.1% in the 4th quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock valued at $16,143,000 after acquiring an additional 497,615 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Corium International by 6.0% in the 4th quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock valued at $2,147,000 after acquiring an additional 12,745 shares during the period. Institutional investors own 94.79% of the company’s stock.

Shares of CORI stock traded up $0.24 on Wednesday, reaching $7.94. 192,204 shares of the company’s stock were exchanged, compared to its average volume of 273,234. Corium International has a 52 week low of $7.24 and a 52 week high of $13.93. The company has a debt-to-equity ratio of 1.89, a quick ratio of 7.95 and a current ratio of 8.11. The firm has a market capitalization of $285.95 million, a P/E ratio of -4.84 and a beta of 1.55.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.